
X
AstraZeneca improves diabetes pen to maintain its market share
https://pharmaphorum.com/news/astrazeneca-improves-diabetes-pen-to-maintain-its-market-share/
But can it seriously challenge Novo Nordisk rival?
Rival insulin and GLP-1 combinations under review in US.